Versartis, Inc. (VSAR) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Versartis, Inc. stock price
Versartis, Inc. latest news:
Versartis growth hormone drug fails key study, shares sink
Sept 21 (Reuters) - Versartis Inc said its
experimental drug for the treatment of growth hormone deficiency
in children did not meet the main goal of a late-stage study,
sending its shares tanking 85 percent.
Versartis shares halted
Shares of Versartis Inc. were halted late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc. , in a study focusing on pediatric growth-hormone deficiency. "We are very surprised and disappointed to learn the outcome," Chief Executive Jay Shepard said in Thursday's announcement, adding that the company planned to provide a corporate update later this year. Versartis shares have gained 27% in the past three months, more than 10 times the gains for the S&P 500 Index in the same period, and nearly 45% so far this year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Vertex Energy, IncVTNR
Vertex Pharmaceuticals IncorporatedVRTX
Vestin Realty Mortgage I, Inc.VRTA
Vestin Realty Mortgage II, Inc.VRTB
Viavi Solutions Inc.VIAV